Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation

Inclusion Criteria:

* To be aged 3 to 65 years
* It was consistent with the diagnosis of CD19+ B-All with MRD+ in allo- hsct transplantation
* The immunotyping was determined to be CD19+ B-All
* The T lymphocytes in the subjects were 100% donor T lymphocytes
* No chemotherapy or antibody treatment was received 2 weeks before cell therapy
* Left ventricular ejection fraction (LVEF) ≥50% and centerless inclusion were diagnosed by echocardiography
* The subjects had no pulmonary active infection
* Blood oxygen saturation at the fingertips ≥ 92%
* Estimated survival of \>3 months
* ECOG physical condition level 0\~1

Exclusion Criteria:

* Unwilling to accept IM19 CAR-T cell therapy, do not agree to signInformed consent of subject
* Subjects are allergic to the components of cellular products
* Total serum bilirubin ≥ 2.0mg/dl、Serum albumin \< 35g/L、ALT and AST were more than 3 times of the upper limit of the normal range. Blood creatinine ≥ 2.0mg/dl;Platelet \< 20 x 109 / L
* Subjects had activity level II-IV aGVHD, or activityModerate to severe cGVHD
* The subjects had a severe failure to control the infection
* Subject with known central nervous system leukemia (CNS2 or CNS3)
* Subjects were treated with CAR T cells or DLT after transplantation
* The subjects developed bone marrow failure syndrome after allo-hsct transplantation
* The subjects had previously received other gene treatments
* The subjects had a history of alcohol, drug use or mental illness
* Subjects were enrolled in any other clinical investigator within 1 month prior to screening
* Female subjects: 1) were pregnant/lactating, or 2) had a pregnancy plan during the study period,Or 3) fertile and unable to use effective contraception
* The researchers believe there are other conditions that may not be appropriate for the study